AnaptysBio, Inc. (NASDAQ:ANAB) Receives Consensus Rating of “Moderate Buy” from Brokerages

AnaptysBio, Inc. (NASDAQ:ANAB) has been given a consensus recommendation of “Moderate Buy” by the twelve brokerages that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average 12 month price target among brokers that have covered the stock in the last year is $54.64.

A number of equities research analysts recently issued reports on ANAB shares. Guggenheim boosted their price objective on AnaptysBio from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Monday, October 21st. HC Wainwright reaffirmed a “buy” rating and set a $55.00 target price on shares of AnaptysBio in a report on Wednesday, August 14th. Truist Financial lifted their target price on AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a report on Thursday, August 15th. Wedbush reaffirmed an “outperform” rating and set a $42.00 target price on shares of AnaptysBio in a report on Thursday, September 26th. Finally, JPMorgan Chase & Co. lifted their target price on AnaptysBio from $69.00 to $75.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th.

AnaptysBio Stock Performance

Shares of AnaptysBio stock opened at $30.80 on Wednesday. AnaptysBio has a 52-week low of $13.36 and a 52-week high of $41.31. The stock’s 50-day simple moving average is $35.23 and its 200 day simple moving average is $29.93. The stock has a market capitalization of $841.43 million, a P/E ratio of -5.02 and a beta of -0.29.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.82). AnaptysBio had a negative net margin of 558.25% and a negative return on equity of 255.68%. The firm had revenue of $10.97 million during the quarter, compared to the consensus estimate of $25.85 million. Equities research analysts forecast that AnaptysBio will post -6.84 EPS for the current fiscal year.

Insider Buying and Selling

In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of the business’s stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total value of $58,005.00. Following the completion of the sale, the insider now owns 15,398 shares in the company, valued at approximately $595,440.66. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of the business’s stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total value of $58,005.00. Following the completion of the sale, the insider now owns 15,398 shares in the company, valued at approximately $595,440.66. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Ecor1 Capital, Llc acquired 273,972 shares of the stock in a transaction on Wednesday, August 14th. The stock was bought at an average price of $36.50 per share, with a total value of $9,999,978.00. Following the transaction, the insider now directly owns 7,794,996 shares of the company’s stock, valued at approximately $284,517,354. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. Insiders sold 22,440 shares of company stock worth $892,936 in the last quarter. 33.70% of the stock is owned by insiders.

Hedge Funds Weigh In On AnaptysBio

A number of hedge funds and other institutional investors have recently made changes to their positions in ANAB. Allspring Global Investments Holdings LLC bought a new position in shares of AnaptysBio during the first quarter valued at approximately $38,000. Values First Advisors Inc. bought a new position in shares of AnaptysBio during the third quarter valued at approximately $49,000. nVerses Capital LLC raised its holdings in shares of AnaptysBio by 700.0% during the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after acquiring an additional 1,400 shares in the last quarter. Headlands Technologies LLC raised its holdings in shares of AnaptysBio by 444.8% during the second quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock valued at $89,000 after acquiring an additional 2,900 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of AnaptysBio by 81.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock valued at $195,000 after acquiring an additional 2,600 shares in the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.